Coronally Advanced Tunnel Combined With Xenogenic Dermal Matrix and L-PRF

Launched by ANDRES MATTEO PASCUAL LA ROCCA · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat gum problems, specifically gingival recession, which is when the gums pull away from the teeth and expose the tooth roots. This condition is common in adults and can worsen over time if not treated. The trial is looking at whether combining a special tissue substitute called Acellular Dermal Matrix (ADM) with a treatment that uses the body's own healing properties, known as Leukocyte and Platelet-Rich Fibrin (L-PRF), can provide better results than using ADM alone. Researchers want to see if this combination can effectively cover the exposed roots and improve the overall health and appearance of the gums after six months.

To participate in this trial, you need to be an adult aged 18 or older with certain gum conditions. You should have good oral hygiene and no serious health issues that would interfere with treatment, such as untreated gum disease or certain chronic illnesses. Participants can expect to undergo a surgical procedure aimed at restoring the gums while minimizing discomfort and improving their smile. This study is not yet recruiting participants, but if you're interested, it could be a chance to contribute to important research in dental health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patients with ≥18 years of age. ability to understand all the study procedures and to comply with them throughout the entire study period. Ability and willingness to give written informed consent.
• • an adequate level of oral hygiene (plaque index ≤ 25%) (O\'Leary et al., 1972).
• • an adequate general bleeding on probing (≤ 20%) treated periodontal disease. presence of two or more adjacent Cairo type I or II gingival recessions, with ≥1mm of keratinized gingiva in all the deffects.
• Exclusion Criteria:
• • untreated periodontitis.
• • smokers \> 5 cigarettes per day.
• • local or systemic diseases that would interfere with routine periodontal therapy (i.e., uncontrolled diabetes mellitus, cancer, HIV, chronic high-dose steroid therapy, metabolic bone disease, radiation, immunosuppressive disease, hepatic dysfunction, immunosuppressive disease, autoimmune disease).
• • treatment with anticoagulants or bisphosphonates.
• • pregnant or lactating women.
• • radiographic interproximal bone loss.
• • tooth Mobility. If present, splinting should be performed prior to treatment.
• • Active orthodontic treatment
• • allergy or intolerance to study medication
• • use of systemic antibiotics during the last 3 months
• • use of systemic antibiotics for endocarditis prophylaxis
• • patients with intentions to change residence that prevent follow-up